Back to Search
Start Over
Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
- Source :
-
Leukemia [Leukemia] 1989 Oct; Vol. 3 (10), pp. 692-4. - Publication Year :
- 1989
-
Abstract
- A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a greater than 40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensive but nonablative treatment plans.
Details
- Language :
- English
- ISSN :
- 0887-6924
- Volume :
- 3
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 2674562